WCM Investment Management LLC Sells 2,072 Shares of Repligen Co. (NASDAQ:RGEN)

WCM Investment Management LLC lessened its position in shares of Repligen Co. (NASDAQ:RGEN) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,086 shares of the biotechnology company’s stock after selling 2,072 shares during the period. WCM Investment Management LLC’s holdings in Repligen were worth $13,962,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of RGEN. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Repligen by 46.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,629 shares of the biotechnology company’s stock worth $2,679,000 after buying an additional 5,913 shares in the last quarter. Alliance Wealth Advisors LLC UT boosted its position in Repligen by 5.9% during the 4th quarter. Alliance Wealth Advisors LLC UT now owns 3,586 shares of the biotechnology company’s stock worth $516,000 after acquiring an additional 199 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after acquiring an additional 6,872 shares in the last quarter. Slow Capital Inc. raised its holdings in shares of Repligen by 3.3% in the fourth quarter. Slow Capital Inc. now owns 16,760 shares of the biotechnology company’s stock valued at $2,412,000 after purchasing an additional 534 shares during the last quarter. Finally, Ballentine Partners LLC lifted its position in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RGEN. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. HC Wainwright lowered their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $184.73.

Repligen Trading Down 3.6 %

RGEN stock opened at $156.05 on Monday. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The stock has a market cap of $8.74 billion, a price-to-earnings ratio of -421.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a fifty day moving average price of $155.37 and a two-hundred day moving average price of $148.93. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.23 EPS. Equities analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.